Abstract:Abstract Background The American Joint Committee on Cancer (AJCC) eighth edition cancer staging manual has updated with a prognostic stage group for breast cancer by incorporating traditional TNM anatomic parameters and biomarkers (ER, PR, Her-2 status and tumor grade, etc.). In this study, we retrospectively compared the prognostic value between the AJCC 8th Edition anatomic and prognostic staging system for triple negative breast cancer(TNBC) in a cohort from two involved institutions and a large population database. Design Clinicopathological data of patients who underwent breast surgery as the initial intervention and with TNBC were identified in Sun Yat-sen University Cancer Center(SYSUCC) during 2005-2013 and Prince of Wales Hospital (PWH) during 2002-2008. Data from surveillance, epidemiology, and end results (SEER) database during 2010-2015 was also accessed. We restaged all cases into anatomic stage (AS) and prognostic stage (PS) group according to the AJCC 8th Edition staging system. The Kaplan-Meier analysis with log-rank test was used to compare differences in disease-specific survival (DSS), overall survival (OS) and progression-free survival (PFS) between groups. The Harrell concordance index (C index) was calculated to measure predictive performance for the AS and PS models. The relationshipof AS and PS with DSS, PFS or OS was examined using a Cox proportional hazards regression model. Results A total of 611 patients with stage I to IIIC TNBC were identified in the SYSUCC-PWH cohort with a median follow-up of 53.5 months. Compared with the AS, PS upstaged 46.1% of patients. No patient was downstaged by PS in this cohort. No significant difference was observed in C index between AS and PS models for either DSS (0.84 vs. 0.83, p=0.943) or PFS (0.82 vs. 0.80, p=0.887), demonstrating that PS do not reflect a more accurate predictive model than AS. A total of 31941 patients with stage I to IIIC TNBC were identified in the SEER cohort with a median follow-up of 27 months. PS upstaged 62.4% of patients and downstaged eight patients (from IIIC to IIIB) in this cohort. Similarly, PS model do not performed better than the AS in either DSS (C index, 0.85 vs. 0.86, p=0.95) or OS (C index, 0.90 vs. 0.90, p=0.98). Compared those with stage changed to other without, in SYSUCC-PWH cohort, patients with IIIC unchanged stage showed worse PFS compared to patients with AS IIIA or IIIB upstaged to PS IIIC (p=0.049). Similarly, in SEER cohort, patients with IIIC unchanged stage showed worse OS and DSS compared to patients with AS IIIA or IIIB upstaged to PS IIIC (p<0.001). Conclusion Our findings demonstrated that PS did not provide better discriminatory ability in predicting TNBCs prognosis than AS. Further update with additional morphological and genomic information regarding the prognostic significance should be incorporated into prognosis staging model for TNBCs. Table 1. 5-year PFS and DSS by AS and PS of TNBCs included in SYSUCC-PWH cohort (N=611)StageNo. at risk5-year PFS (95% CI)p-value5-year DSS (95% CI)p-valueASI(A*)10086.5(76.2,92.5)<0.001**92.9(83.4,97.0)0.001**II37182.0(77.0,86.0)0.001#90.6(86.3,93.6)0.080#IIA24087.9(82.4,91.9)92.7(87.7,95.7)IIB13171.0(60.9,79.0)86.2(76.8,92.0)III14050.9(41.1,59.8)0.045Δ74.1(64.2,81.7)0.099ΔIIIA7856.6(43.7,67.6)80.4(67.8,88.5)IIIB2955.2(28.6,75.4)51.4(23.1,73.9)IIIC3334.9(18.3,52.2)70.4(46.9,85.0)PSI10086.5(76.2,92.5)<0.001**92.9(83.4,97.0)<0.001**IA3NANAIB9786.0(75.4,92.3)92.7(88.5,97.0)II29183.9(78.3,88.2)0.002#91.9(87.2,94.9)0.209#IIA24087.9(82.4,91.9)92.7(89.7,95.7)IIB5164.1(46.1,77.5)87.3(79.4,95.1)III22060.1(52.3,66.9)<0.001Δ78.2(70.7,83.9)0.023ΔIIIA8374.7(62.2,83.6)85.5(78.7,92.3)IIIB2673.7(50.4,87.3)83.5(72.5,94.5)IIIC11144.9(34.0,55.1)70.7(61.8,79.7) Table 2. 5-year OS and DSS by AS and PS of TNBCs included in SEER cohort (N=31941)StageNo. at risk5-year OS (95% CI)p-value5-year DSS (95% CI)p-valueASI1270087.2(86.2,88.0)<0.001**93.5(82.8,94.2)<0.001**IA1229387.4(86.5,88.3)0.004*93.8(93.1,94.4)0.001*IB40780.4(73.9,85.5)86.2(80.6,90.2)II1429275.3(74.2,76.4)<0.001#82.7(81.8,83.7)<0.001#IIA971378.5(77.2,79.7)86.0(84.9,87.0)IIB457968.3(66.1,70.4)75.5(73.5,77.4)III494946.8(44.8,48.7)<0.001Δ54.0(52.0,56.0)<0.001ΔIIIA251557.1(54.3,59.7)63.6(60.8,66.2)IIIB116438.5(34.5,42.5)47.0(42.6,51.2)IIIC127034.3(30.5,38.2)41.4(37.3,45.2)PSI1229387.4(86.5,88.3)<0.001**93.8(93.1,94.4)<0.001**IA40789.4(83.6,93.2)0.212*94.6(89.2,97.3)0.259*IB1188687.4(86.5,88.3)93.8(93.1,94.4)II1072677.9(76.7,79.1)<0.001#85.5(84.4,86.5)<0.001#IIA1012078.6(77.3,79.8)86.0(85.0,87.0)IIB60667.4(61.2,72.9)75.4(69.3,80.4)III892256.3(54.8,57.8)<0.001Δ63.5(62.0,65.0)<0.001ΔIIIA398668.7(66.4,70.8)75.6(73.4,77.6)IIIB36556.3(47.8,64.0)62.1(53.0,70.0)IIIC457145.9(43.9,48.0)53.3(51.2,55.4) Citation Format: Peng Sun, JYS Tsang, Xiaodan Xu, Jibin Li, Mei Li, Xue Chao, Rongzhen Luo, Gary Tse, Jiehua He. AJCC 8th edition prognostic staging system provide no better discriminatory ability in prognosis than anatomical staging system in triple negative breast cancer: A cohort from two institutions and a large population based study [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P5-06-19.

Abstract P5-06-19: AJCC 8th Edition Prognostic Staging System Provide No Better Discriminatory Ability in Prognosis Than Anatomical Staging System in Triple Negative Breast Cancer: A Cohort from Two Institutions and a Large Population Based Study

AJCC 8th edition prognostic staging system provide no better discriminatory ability in prognosis than anatomical staging system in triple negative breast cancer: A cohort from two institutions and a large population based study

AJCC 8th edition prognostic staging provides no better discriminatory ability in prognosis than anatomical staging in triple negative breast cancer

The Predictive Value of the Prognostic Staging System in the 8th Edition of the American Joint Committee on Cancer for Triple-Negative Breast Cancer: a SEER Population-Based Analysis

Prognostic Stage Groups Established by AJCC Staging System 8th Edition Does Not Significantly Improve Discrimination over Classic TNM Staging in Early Stage Breast Cancer Treated with Breast Conservative Therapy

Validation of the Prognostic Significance of the Prognostic Stage Group According to the Eighth Edition of American Cancer Joint Committee on Cancer Staging System in Triple-Negative Breast Cancer: An Analysis From Surveillance, Epidemiology, and End Results 18 Database

Triple-negative breast cancer outcomes: Does AJCC 8th staging improve chemotherapy decision-making

[A retrospective analysis on the prognostic evaluation of triple-negative breast cancer with prognostic staging according to the AJCC Breast Cancer Staging System, Eighth Edition]

A Retrospective Survival Analysis of Anatomic and Prognostic Stage Group Based on the American Joint Committee on Cancer 8th Edition Cancer Staging Manual in Luminal B Human Epidermal Growth Factor Receptor 2-negative Breast Cancer.

Evaluation of the Incorporation of Recurrence Score into the American Joint Committee on Cancer Eighth Edition Staging System in Patients with T1-2N0M0, Estrogen Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Invasive Breast Cancer: A Population-Based Analysis

Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer

Validation of the Eighth American Joint Committee on Cancer Anatomic and Prognostic Staging System for Breast Cancer

The Prognostic and Predictive Value of the 8th American Joint Committee on Cancer (AJCC) Staging System among Early Breast Cancer Patients Aged <50 Years

Evaluation of the 8th Edition of the American Joint Committee on Cancer's Pathological Staging System in Prognosis Assessment and Treatment Decision Making for Stage T1-2N1 Breast Cancer after Mastectomy.

Prognostic Validation and Therapeutic Decision-Making of the AJCC Eighth Pathological Prognostic Staging for T3N0 Breast Cancer after Mastectomy

Validation of the pathological prognostic staging system proposed in the revised eighth edition of the AJCC staging manual in different molecular subtypes of breast cancer

Validation of the Prognostic Stage from the American Joint Committee on Cancer 8th Staging Manual in Luminal B-Like Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

Validation of the newly proposed American Joint Committee on Cancer (AJCC) breast cancer prognostic staging group and proposing a new staging system using the National Cancer Database

Prognosic Stage Groups Established By Ajcc Staging System 8th Edition May Help To Individualize Postmastectomy Radiation Therapy In T1-2n1m0 Breast Cancer

Comparison of the 7th and 8th edition of American Joint Committee on Cancer (AJCC) staging systems for breast cancer patients: a Surveillance, Epidemiology and End Results (SEER) Analysis.

Evaluation of the prognostic stage in the 8th edition of the American Joint Committee on Cancer in locally advanced breast cancer: An analysis based on SEER 18 database.